Get the Stockscreener App
1.60
4.76%
-0.08
After Hours:
1.60
Coherus Oncology Inc stock is traded at $1.60, with a volume of 999.89K.
It is down -4.76% in the last 24 hours and down -2.44% over the past month.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
See More
Previous Close:
$1.68
Open:
$1.69
24h Volume:
999.89K
Relative Volume:
0.82
Market Cap:
$124.16M
Revenue:
$257.24M
Net Income/Loss:
$-237.89M
P/E Ratio:
-0.6154
EPS:
-2.6
Net Cash Flow:
$-175.17M
1W Performance:
+0.00%
1M Performance:
-2.44%
6M Performance:
+45.45%
1Y Performance:
+121.30%
1-Day Range:
$1.57
$1.72
1-Week Range:
$1.57
$1.805
52-Week Range:
$0.6603
$2.43
Coherus Oncology Inc Stock (CHRS) Company Profile
Name
Coherus Oncology Inc
Sector
Industry
Phone
(650) 649-3530
Address
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Compare CHRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CHRS
Coherus Oncology Inc
|
1.60 | 195.26M | 257.24M | -237.89M | -175.17M | -2.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Upgrade | Maxim Group | Hold → Buy |
| Aug-16-24 | Downgrade | UBS | Buy → Neutral |
| Nov-17-23 | Initiated | Robert W. Baird | Outperform |
| Nov-08-23 | Downgrade | Maxim Group | Buy → Hold |
| Jul-24-23 | Initiated | Citigroup | Buy |
| May-01-23 | Initiated | Truist | Buy |
| Mar-28-23 | Upgrade | UBS | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Neutral |
| Mar-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-16-20 | Initiated | BofA Securities | Neutral |
| Apr-17-20 | Initiated | SunTrust | Buy |
| Aug-13-19 | Initiated | Mizuho | Buy |
| Aug-02-19 | Reiterated | H.C. Wainwright | Buy |
| Aug-02-19 | Reiterated | Maxim Group | Buy |
| Jun-11-19 | Initiated | Barclays | Overweight |
| May-07-19 | Initiated | H.C. Wainwright | Buy |
| Aug-28-18 | Initiated | H.C. Wainwright | Buy |
| Mar-09-18 | Reiterated | Maxim Group | Buy |
| Aug-08-17 | Reiterated | JP Morgan | Overweight |
| Jun-13-17 | Reiterated | Maxim Group | Buy |
| May-05-17 | Initiated | BMO Capital Markets | Outperform |
| Oct-19-16 | Initiated | Robert W. Baird | Outperform |
| Sep-07-16 | Initiated | Maxim Group | Buy |
| Jul-27-16 | Initiated | Citigroup | Buy |
| Jan-20-16 | Initiated | Credit Suisse | Outperform |
View All
Coherus Oncology Inc Stock (CHRS) Latest News
3 Penny Stocks With Market Caps Over $80M To Consider - Yahoo Finance
Coherus Oncology's (NASDAQ:CHRS) investors will be pleased with their solid 132% return over the last year - Yahoo Finance
Can Coherus Oncology Inc. (8C5) stock retain market dominanceMarket Activity Report & Long-Term Safe Investment Plans - newser.com
Will Coherus BioSciences Inc. stock recover faster than marketBuy Signal & Breakout Confirmation Trade Signals - newser.com
Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025 - The Manila Times
Coherus Oncology (NASDAQ: CHRS) schedules Nov. 6 results release and 5 p.m. ET call - Stock Titan
CapEx per share of Coherus Oncology, Inc. – DUS:8C5 - TradingView
Coherus Oncology, Inc. (NASDAQ:CHRS) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Coherus Oncology (CHRS) to Release Quarterly Earnings on Wednesday - MarketBeat
How Coherus Oncology Inc. (8C5) stock performs during market turbulenceLayoff News & Scalable Portfolio Growth Methods - newser.com
Despite shrinking by US$22m in the past week, Coherus Oncology (NASDAQ:CHRS) shareholders are still up 122% over 1 year - simplywall.st
Aug Ideas: How Coherus Oncology Inc. (8C5) stock performs during market turbulenceJuly 2025 Retail & Consistent Profit Trading Strategies - Fundação Cultural do Pará
Coherus Oncology (NASDAQ:CHRS) Given "Sell (D)" Rating at Weiss Ratings - MarketBeat
Will Coherus BioSciences Inc. stock deliver better than expected guidanceLayoff News & Real-Time Volume Surge Alerts - newser.com
Coherus Oncology (NASDAQ:CHRS) Share Price Crosses Above 200 Day Moving AverageHere's Why - MarketBeat
What analysts say about Coherus Oncology Inc 8C5 stockStock Buy Signals & Maximum Profit Growth - earlytimes.in
Will Coherus Oncology Inc. (8C5) stock benefit from infrastructure billPortfolio Risk Report & Risk Controlled Swing Trade Alerts - newser.com
Coherus Oncology to Participate in Upcoming Investor Conferences - The Manila Times
Will Coherus Oncology Inc. (8C5) stock outperform value peersBuy Signal & Community Verified Trade Alerts - newser.com
Lobbying Update: $80,000 of COHERUS BIOSCIENCES INC. lobbying was just disclosed - Quiver Quantitative
What dividend safety rating applies to Coherus Oncology Inc. (8C5) stock2025 Volume Leaders & Expert Curated Trade Ideas - newser.com
Why Coherus Oncology Inc. (8C5) stock is trending on social media2025 Geopolitical Influence & Long Hold Capital Preservation Tips - newser.com
Guidance Update: Will Coherus Oncology Inc. (8C5) stock outperform value peersJuly 2025 Momentum & Long-Term Growth Portfolio Plans - nchmf.gov.vn
Stock Market Recap: Will Coherus Oncology Inc. (8C5) stock outperform value peersJuly 2025 Trends & Technical Pattern Recognition Alerts - Trung tâm Dự báo KTTV quốc gia
CHRS (Coherus Oncology) EBITDA Margin % : -405.39% (As of Jun. 2025) - GuruFocus
Coherus Oncology, Inc.Common Stock (Nasdaq:CHRS) Stock Quote | Oklahoma City NewsThe Oklahoman - FinancialContent
How Coherus Oncology Inc. (8C5) stock reacts to monetary easing2025 Dividend Review & Real-Time Market Trend Scan - newser.com
Coherus Oncology (NASDAQ:CHRS) Share Price Passes Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
What technical patterns form on Coherus Oncology Inc. (8C5) stock chartsMarket Sentiment Review & Weekly Return Optimization Plans - newser.com
Revenue per share of Coherus Oncology, Inc. – MUN:8C5 - TradingView
4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals - inkl
How strong dollar benefits Coherus Oncology Inc. (8C5) stockJuly 2025 Price Swings & Weekly Hot Stock Watchlists - newser.com
Coherus Oncology Inc Stock (CHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):